Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.

Brown A, Patel SS, Li E, Vu AH, Somoza E, Chen J, Zhang D, Massie AB, Orandi BJ, Segev D, Parikh M, Chhabra K

Surgical endoscopy1 Dec 2025Cited by 3 (Europe PMC)

PMID41326727 (opens in a new tab)DOI10.1007/s00464-025-12403-y (opens in a new tab)PepBankPUB-41326727
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In publicly insured adults with obesity and type 2 diabetes, pooled GLP-1 receptor agonist users (semaglutide or tirzepatide) lost 2.3% of body weight at 3 years versus 22.9% with bariatric surgery.

    In plain wordsIn publicly insured adults with obesity and diabetes, people on GLP-1 drugs lost far less weight at 3 years than people with bariatric surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal body weight loss at 3 years, any GLP-1RA use
    Study

    n = 7,667

    Comparator
    Bariatric surgery
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Total weight loss at 3 years
    2.3%
    any GLP-1RA use
    Total weight loss at 3 years
    22.9%
    bariatric surgery

    Source sentences

    Summary
    bariatric surgery was associated with a 22.9% total weight loss 3 years following surgery compared to 2.3% for patients with any GLP1-RA use
    2 context sentences
    Summary · context
    This was a retrospective, multicenter study of obese, type-2 diabetic patients (T2D) ≥ 18 years old, who initiated weekly injectable semaglutide or tirzepatide or underwent bariatric surgery between January 1st, 2018 to July 31st, 2024.
    Summary · context
    7667 patients were included for analysis (7200 GLP1-RA, 467 bariatric surgery).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In publicly insured adults with obesity and type 2 diabetes, pooled GLP-1 receptor agonist users (semaglutide or tirzepatide) lost 2.3% of body weight at 3 years versus 22.9% with bariatric surgery.

    In plain wordsIn publicly insured adults with obesity and diabetes, people on GLP-1 drugs lost far less weight at 3 years than people with bariatric surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal body weight loss at 3 years, any GLP-1RA use
    Study

    n = 7,667

    Comparator
    Bariatric surgery
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Total weight loss at 3 years
    2.3%
    any GLP-1RA use
    Total weight loss at 3 years
    22.9%
    bariatric surgery

    Source sentences

    Summary
    bariatric surgery was associated with a 22.9% total weight loss 3 years following surgery compared to 2.3% for patients with any GLP1-RA use
    2 context sentences
    Summary · context
    This was a retrospective, multicenter study of obese, type-2 diabetic patients (T2D) ≥ 18 years old, who initiated weekly injectable semaglutide or tirzepatide or underwent bariatric surgery between January 1st, 2018 to July 31st, 2024.
    Summary · context
    7667 patients were included for analysis (7200 GLP1-RA, 467 bariatric surgery).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In publicly insured adults with obesity and type 2 diabetes, pooled GLP-1 receptor agonist users with 12 months of continuous use lost 2.4% of body weight at 3 years versus 15.9% with bariatric surgery.

    In plain wordsIn adults with obesity and diabetes, people with 12 months of steady GLP-1 drug use lost less weight than those with bariatric surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal body weight loss at 3 years, 12 months continuous GLP-1RA use
    Study

    n: not reported in source

    Comparator
    Bariatric surgery
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Total weight loss at 3 years
    2.4%
    12 months continuous GLP-1RA use
    Total weight loss at 3 years
    15.9%
    bariatric surgery

    Source sentences

    Summary
    15.9% vs 2.4% for patients with 12 months consecutive GLP1-RA use
    2 context sentences
    Summary · context
    This was a retrospective, multicenter study of obese, type-2 diabetic patients (T2D) ≥ 18 years old, who initiated weekly injectable semaglutide or tirzepatide or underwent bariatric surgery between January 1st, 2018 to July 31st, 2024.
    Summary · context
    7667 patients were included for analysis (7200 GLP1-RA, 467 bariatric surgery).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In publicly insured adults with obesity and type 2 diabetes, pooled GLP-1 receptor agonist users with 12 months of continuous use lost 2.4% of body weight at 3 years versus 15.9% with bariatric surgery.

    In plain wordsIn adults with obesity and diabetes, people with 12 months of steady GLP-1 drug use lost less weight than those with bariatric surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal body weight loss at 3 years, 12 months continuous GLP-1RA use
    Study

    n: not reported in source

    Comparator
    Bariatric surgery
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Total weight loss at 3 years
    2.4%
    12 months continuous GLP-1RA use
    Total weight loss at 3 years
    15.9%
    bariatric surgery

    Source sentences

    Summary
    15.9% vs 2.4% for patients with 12 months consecutive GLP1-RA use
    2 context sentences
    Summary · context
    This was a retrospective, multicenter study of obese, type-2 diabetic patients (T2D) ≥ 18 years old, who initiated weekly injectable semaglutide or tirzepatide or underwent bariatric surgery between January 1st, 2018 to July 31st, 2024.
    Summary · context
    7667 patients were included for analysis (7200 GLP1-RA, 467 bariatric surgery).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.